Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

- PMLiVE

Gilead awaits CEO and readouts to revive fortunes

NASH and oral RA drugs set for crucial readouts

- PMLiVE

NICE and Canadian counterpart to offer joint advice service

Agencies offer parallel scientific advice

Six factors that drive a multiple sclerosis patient’s choice of disease-modifying therapy

MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.

Blue Latitude Health

- PMLiVE

OPEN Health unveils restructuring

Eight of the agencies will come together under four practices

- PMLiVE

New faces at GCI Health, Porterhouse Medical and Research Partnership

The latest movers in healthcare communications

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

Novo Nordisk preps for speedy oral GLP-1 drug filing

Needs to compete with rival's fast-growing Trulicity

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

Havas Lynx Group scoops nine Golds at PM Society Awards

Sanofi Genzyme and Regeneron topped the pharma company charts

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links